Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.
May Ee PngVictoria HarrisJenna GrabeyNigel David HartBhautesh Dinesh JaniDaniel ButlerAndrew Carson-StevensMaria CoatesLucy CuretonMelissa DobsonJienchi DorwardPhilip EvansNick A FrancisOghenekome Abisoye GbinigieGail HaywardJane HolmesKerenza HoodSaye KhooHaroon AhmedMark LownMicheal MckennaSam MortJonathan Nguyen-Van-TamNajib RahmanDuncan B RichardsNicholas ThomasOliver van HeckeFrederick David Richard HobbsPaul LittleLy-Mee YuChristopher C ButlerStavros PetrouPublished in: The British journal of general practice : the journal of the Royal College of General Practitioners (2024)
Molnupiravir at the current cost of £513 per course is unlikely to be cost-effective relative to usual care over a six-month time horizon among mainly vaccinated COVID-19 patients at increased risk of adverse outcomes, except those aged ≥75 years.